KBI Biopharma Partners with Alanis Therapeutics for mAb Development in Blood Cancer Treatment

• KBI Biopharma, a global cGMP contract development and manufacturing organisation (CDMO), has secured a contract with Alanis Therapeutics for the development of a pre-clinical therapeutic antibody for blood cancers.

• The collaboration will utilise KBI’s SUREmAb platform to optimise and streamline the production of Alanis’ lead monoclonal antibody (mAb).

KBI Biopharma, Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has entered into a manufacturing agreement with Alanis Therapeutics, Inc. to develop a pre-clinical therapeutic antibody aimed at treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The partnership will see KBI overseeing a range of services, including cell line development, process optimisation, and the manufacture of Alanis’ innovative monoclonal antibody (mAb).

The collaboration will leverage KBI’s proprietary SUREmAb platform, a state-of-the-art technology designed to streamline the production of monoclonal antibodies. This platform will allow KBI to accelerate and optimise the mAb production process, moving Alanis Therapeutics closer to clinical trials and eventual investigational new drug (IND) submission.

Dr. Robert Goodenow, CEO of Alanis Therapeutics, commented, “We are pleased to select KBI as our trusted CDMO to advance our lead antibody to the Notch pathway. By collaborating with KBI, we aim to accelerate the development process and move closer to evaluating the full therapeutic potential of our antibody in clinical trials.”

Tim Lowery, CEO of KBI Biopharma and President of JSR Life Sciences, stated, “We are proud to support Alanis and spearhead the development of its lead target. Our integrated workflow, high productivity, and streamlined process provide a fast path from cell line transfection to the final stages of cGMP drug substance manufacturing.”